Soligenix
29 Emmons Drive
Suite C-10
Princeton
New Jersey
08540
United States
Tel: 609-538-8200
Fax: 609-452-6467
Website: http://www.soligenix.com/
414 articles about Soligenix
-
Soligenix Announces Recent Accomplishments and Year End 2023 Financial Results
3/15/2024
Soligenix, Inc. announced today its recent accomplishments and financial results for the year ended December 31, 2023.
-
Soligenix Announces Formation of Behçet's Disease Medical Advisory Board
2/8/2024
Soligenix, Inc. announced today the formation of a Medical Advisory Board (MAB) to provide medical/clinical strategic guidance to the Company as it advances the clinical development of SGX945 (dusquetide) for the treatment of Behçet's Disease.
-
Soligenix to Present at The Microcap Conference
1/25/2024
Soligenix, Inc. today that the Company will deliver a corporate presentation at The Microcap Conference.
-
FDA Grants Soligenix "Fast Track" Designation for Dusquetide in the Treatment of Oral Lesions of Behçet's Disease
1/8/2024
Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company) announced today that its SGX945 (dusquetide) development program for the treatment of oral lesions of Behçet's Disease has received "Fast Track" designation from the U.S. Food and Drug Administration (FDA).
-
Soligenix Announces Top-line Results of the Phase 2a Study of SGX302 (Synthetic Hypericin) in Patients with Mild-to-Moderate Psoriasis
1/4/2024
Soligenix, Inc. announced today preliminary top-line results of its ongoing Phase 2a trial of SGX302 (synthetic hypericin) for the treatment of mild-to-moderate psoriasis.
-
Soligenix Announces Publication Demonstrating Complete Protection Against Filovirus Disease in Nonhuman Primate Models of Ebola and Marburg Viruses
1/2/2024
Soligenix, Inc. announced today a publication describing the preclinical efficacy of a novel, single-vial, bivalent vaccine providing 100% protection against both Sudan ebolavirus (SUDV) and Marburg marburgvirus (MARV) infections.
-
"HyBryte™ Use in Early-Stage Cutaneous T-Cell Lymphoma" Published in Frontiers in Drug Discovery
12/1/2023
Soligenix, Inc. announced that an article describing the potential use of HyBryte™ in the treatment of cutaneous T-cell lymphoma has been published in Frontiers in Drug Discovery.
-
Soligenix Receives FDA IND Clearance for Phase 2 Clinical Trial of Dusquetide in the Treatment of Aphthous Ulcers in Behçet's Disease
11/30/2023
Soligenix, Inc. announced today that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for a Phase 2a clinical trial entitled, "Pilot Study of SGX945 (Dusquetide) in the Treatment of Aphthous Ulcers in Behçet's Disease."
-
Soligenix Announces Recent Accomplishments And Third Quarter 2023 Financial Results
11/13/2023
Soligenix, Inc. announced today its recent accomplishments and financial results for the quarter ended September 30, 2023.
-
Soligenix, Inc. Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting
10/20/2023
Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that its 2023 Annual Meeting of Stockholders (the "Annual Meeting").
-
Soligenix to Present at The ThinkEquity Conference
10/16/2023
Soligenix, Inc., a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced that the Company will deliver a corporate presentation at the upcoming ThinkEquity Conference.
-
Soligenix Announces Achievement of Two-Year Stability with Bivalent and Trivalent Thermostabilized Filovirus Vaccines when Stored at High Temperatures
9/25/2023
Soligenix, Inc. announced today two-year stability of its thermostabilized bivalent and trivalent filovirus vaccine candidates at temperatures of 40 degrees Celsius (104 degrees Fahrenheit) when formulated in a single vial, needing reconstitution only with sterile water immediately prior to use.
-
Soligenix, Inc. Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting and Additional Proposal to be Considered by Stockholders
9/22/2023
Soligenix, Inc. announced that its 2023 Annual Meeting of Stockholders scheduled for and convened on September 21, 2023 has been adjourned for the purpose of soliciting additional votes with respect to the proposals described in the Company's definitive proxy statement for the Annual Meeting filed with the Securities and Exchange Commission on August 7, 2023.
-
Soligenix Announces Recent Accomplishments And Second Quarter 2023 Financial Results
8/21/2023
Soligenix, Inc. announced today its recent accomplishments and financial results for the quarter ended June 30, 2023.
-
HyBryte™ Expanded Treatment Trial in Cutaneous T-Cell Lymphoma Opens Enrollment
8/10/2023
Soligenix, Inc. announced today that patient enrollment has been opened for the investigator-initiated study (IIS) at the University of Pennsylvania, supported by a $2.6 million Orphan Products Development grant award by the U.S. Food and Drug Administration (FDA).
-
Soligenix Announces Expansion of SGX302 (Synthetic Hypericin) Phase 2a Study in Mild-to-Moderate Psoriasis
7/11/2023
Soligenix, Inc. announced today the expansion of its Phase 2a trial of SGX302 (synthetic hypericin) for the treatment of mild-to-moderate psoriasis after demonstration of biological effect in the initial five subjects.
-
Soligenix Announces European Patent Grant for Use of Dusquetide in Oral Mucositis
5/16/2023
Soligenix, Inc. announced today that the European Patent Office has granted a patent entitled "Novel Peptides and Analogs for Use in the Treatment of Oral Mucositis".
-
Soligenix Announces Recent Accomplishments And First Quarter 2023 Financial Results
5/15/2023
Soligenix, Inc. announced today its recent accomplishments and financial results for the quarter ended March 31, 2023.
-
Soligenix Announces Scheduling of Type A Meeting with the U.S. FDA to Review Proposed Study Design for a Second Phase 3 Study Evaluating HyBryte™ in the Treatment of Cutaneous T-Cell Lymphoma
5/11/2023
Soligenix, Inc. announced today that the United States (U.S.) Food and Drug Administration (FDA) has granted a Type A meeting to discuss the design of a second, Phase 3 pivotal study evaluating HyBryte™ (hypericin sodium) in the treatment of early stage cutaneous T-cell lymphoma (CTCL), a rare cancer, where it has successfully demonstrated statistically significant results in the first Phase 3 clinical trial.
-
Soligenix Announces Closing of $8.5 Million Public Offering
5/9/2023
Soligenix, Inc. announced the closing of its previously announced public offering of 6,538,500 shares of common stock and common warrants to purchase up to 6,538,500 shares of common stock at a combined public offering price of $1.30.